If you’re working in cancer drug discovery, it’s no secret that proteolysis targeting chimeras (PROTACs) hold great promise for developing innovative new treatments. We’ve seen that these bifunctional molecules can remove unwanted proteins by inducing selective intracellular proteolysis, making them potentially applicable in several areas of oncology. But despite all this burgeoning potential, the
Read More